ArticleBioanalysis
Method qualification of an electrochemiluminescence assay to quantitate anti-FcεR1α autoantibodies: a case study of an antibody-based biomarker.
Article in Bioanalysis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic spontaneous urticaria is a common immunological disease that affects over 1% of the population. Recently, the anti-FcεR1α autoantibody has been discovered as a prominent biomarker related to the disease. Therefore, there is a need for robust, qualified assays to characterize and measure anti-FcεR1α autoantibodies in human serum. However, biomarker assay qualification is a topic of discussion and can sometimes be left open to interpretation. Currently, there is little guidance or best practices outlined for the method qualification of autoantibodies. These molecules are typically endogenous and such assays fall somewhere between quantitative and qualitative.Herein, we develop an electrochemiluminescence assay for the detection of anti-FcεR1α autoantibodies and provide an outline of method qualification. Two assay formats are investigated with one being fully developed and optimized. Other considerations stemming from immunogenicity qualifications are also assessed, such as isotyping, cut-point, and a confirmatory assay.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.